SS Innovations International (NASDAQ: SSII), a developer of surgical robotic technologies, is scaling its SSi Mantra system from an established base in India into international markets, according to recent financial results and company announcements. The company's second-quarter revenue rose 39.4% year over year to $13.9 million, with 30 SSi Mantra systems installed during the quarter.
As of the first half of 2026, SSII reported having 224 systems installed across 12 countries, with more than 12,000 cumulative procedures performed using the platform. This installed base outside its home market marks a significant step in the company's commercialization strategy.
The SSi Mantra system is a surgical robotic platform designed to assist surgeons in performing minimally invasive procedures. The company's growth trajectory is underpinned by increasing adoption at hospitals and a rising number of procedures, which together demonstrate the system's clinical utility and market acceptance.
Looking ahead, potential regulatory clearance in the United States and CE marking in Europe could materially enlarge SSII's addressable market. These approvals would allow the company to enter two of the world's largest medical-device markets, potentially driving further growth.
Investors view the investment case as attractive because SSII is still early in its commercialization curve, with significant room for expansion. However, they must weigh cash consumption, regulatory risk, and potential dilution against the company's growth prospects.
The company's progress is part of a broader trend in the surgical robotics industry, which is seeing increasing competition and innovation. SSII's focus on making advanced surgical technology accessible in emerging markets, starting with India, positions it to capitalize on growing demand for minimally invasive surgery globally.
For more information on SS Innovations, visit the company's newsroom at https://ibn.fm/SSII. The full terms of use and disclaimers can be reviewed at https://IBN.ai/Disclaimer.
This article contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Factors that could affect performance are detailed in the company's filings with the SEC, including its most recent Annual Report on Form 10-K and subsequent quarterly reports.
